Humana Inc (NYSE:HUM) SVP Jody L. Bilney sold 7,054 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the completion of the transaction, the senior vice president now owns 11,704 shares in the company, valued at approximately $2,901,304.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of Humana Inc (NYSE HUM) traded up $2.81 during trading on Friday, hitting $268.02. The stock had a trading volume of 1,573,430 shares, compared to its average volume of 1,016,461. The stock has a market capitalization of $37,887.92, a price-to-earnings ratio of 21.09, a P/E/G ratio of 1.73 and a beta of 0.88. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.61 and a current ratio of 1.61. Humana Inc has a 1 year low of $186.25 and a 1 year high of $271.99.
Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating the consensus estimate of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same quarter last year, the firm posted $3.18 earnings per share. The business’s revenue for the quarter was down 3.0% on a year-over-year basis. research analysts forecast that Humana Inc will post 11.63 earnings per share for the current year.
Humana declared that its board has initiated a stock repurchase plan on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be paid a $0.40 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.60 annualized dividend and a yield of 0.60%. Humana’s dividend payout ratio (DPR) is presently 12.59%.
A number of institutional investors and hedge funds have recently bought and sold shares of HUM. Janus Henderson Group PLC grew its stake in Humana by 7,848.8% in the second quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock valued at $377,192,000 after purchasing an additional 1,547,866 shares during the last quarter. FMR LLC grew its stake in shares of Humana by 29.3% during the second quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock worth $1,571,264,000 after acquiring an additional 1,479,210 shares during the last quarter. Koch Industries Inc. purchased a new stake in shares of Humana during the second quarter worth about $404,000. TIAA CREF Investment Management LLC grew its stake in shares of Humana by 39.7% during the second quarter. TIAA CREF Investment Management LLC now owns 1,358,617 shares of the insurance provider’s stock worth $326,910,000 after acquiring an additional 386,162 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Humana by 39.8% during the second quarter. Ameriprise Financial Inc. now owns 1,322,413 shares of the insurance provider’s stock worth $318,216,000 after acquiring an additional 376,177 shares during the last quarter. Institutional investors own 94.01% of the company’s stock.
HUM has been the subject of several analyst reports. Cowen reissued an “outperform” rating and issued a $275.00 target price (up from $230.00) on shares of Humana in a report on Wednesday, September 20th. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $273.00 price objective for the company in a report on Tuesday, October 3rd. JPMorgan Chase & Co. lowered shares of Humana from an “overweight” rating to a “neutral” rating and set a $253.00 price objective for the company. in a report on Monday, October 9th. ValuEngine lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $245.00 price objective on shares of Humana in a report on Tuesday, October 10th. Ten research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Humana has an average rating of “Buy” and an average price target of $258.90.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/insider-selling-humana-inc-hum-svp-sells-1748616-06-in-stock.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.